- Home
- SLDB
as 11-15-2024 4:00pm EST
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | CHARLESTOWN |
| Market Cap: | 212.2M | IPO Year: | 2018 |
| Target Price: | $17.50 | AVG Volume (30 days): | 295.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.91 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.21 - $15.05 | Next Earning Date: | 11-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Solid Biosciences Inc. (SLDB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Brooks Gabriel | SLDB | Chief Medical Officer | Oct 18 '24 | Sell | $6.50 | 2,923 | $18,999.50 | 10,979 |
Latest Solid Biosciences Inc. News
SLDB Breaking Stock News: Dive into SLDB Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Solid Biosciences to Present at the Jefferies London Healthcare Conference
Simply Wall St.
8 days ago
We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate
GlobeNewswire
11 days ago
Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire
13 days ago
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
17 days ago
Solid Biosciences to Participate at the Truist Securities BioPharma Symposium
GlobeNewswire
2 months ago
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2 months ago
Solid Biosciences to Participate at Chardan’s 8th Annual Genetic Medicines Conference
GlobeNewswire
2 months ago
Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference
Compare SLDB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLDB Solid Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.